Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia

Comprehensive genomic profiling examinations (CGPs) have recently been developed, and a variety of tumor-agnostic mutations have been detected, leading to the development of new molecular-targetable therapies across solid tumors. In addition, the elucidation of hereditary tumors, such as breast and...

Full description

Saved in:
Bibliographic Details
Published in:Biomedicines 2022-11, Vol.10 (12), p.3008
Main Authors: Arai, Hironori, Minami, Yosuke, Chi, SungGi, Utsu, Yoshikazu, Masuda, Shinichi, Aotsuka, Nobuyuki
Format: Article
Language:English
Subjects:
Acute myeloid leukemia
BRCA1 protein
Breast cancer
Cancer therapies
Cell cycle
Cell growth
Clinical trials
DNA methylation
Drug therapy
FDA approval
Fibroblast growth factor receptors
Genes
genomic profiling
Growth factors
Hematology
hereditary breast and ovarian cancer
Janus kinase 2
Kinases
Leukemia
Medical prognosis
Mutation
Ovarian cancer
p53 Protein
Proteins
Review
Sarcoma
solid tumor
Solid tumors
Structure-function relationships
tumor agnostic
Tumors
variant
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Comprehensive genomic profiling examinations (CGPs) have recently been developed, and a variety of tumor-agnostic mutations have been detected, leading to the development of new molecular-targetable therapies across solid tumors. In addition, the elucidation of hereditary tumors, such as breast and ovarian cancer, has pioneered a new age marked by the development of new treatments and lifetime management strategies required for patients with potential or presented hereditary cancers. In acute myeloid leukemia (AML), however, few tumor-agnostic or hereditary mutations have been the focus of investigation, with associated molecular-targeted therapies remaining poorly developed. We focused on representative tumor-agnostic mutations such as the , , , , , , , and genes, referring to a CGP study conducted in Japan, and we considered the possibility of developing molecular-targeted therapies for AML with tumor-agnostic mutations. We summarized the frequency, the prognosis, the structure and the function of these mutations as well as the current treatment strategies in solid tumors, revealed the genetical relationships between solid tumors and AML and developed tumor-agnostic molecular-targeted therapies and lifetime management strategies in AML.
ISSN:2227-9059
2227-9059
DOI:10.3390/biomedicines10123008